An Early Phase 1 interventional study of REGEND007 Cell Therapy in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Regend Therapeutics. Not yet recruiting at 1 site in China. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by Regend Therapeutics · Early Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.
Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 54th largest by planned enrollment of the 60 interventional ones that give a count, is one of 13 that started in 2026, is one of 20 in phase 1, reaches primary completion later than 11 of the 28 other live ones, and was the 56th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:
InSilico Medicine Hong Kong Limited · Sites in China
Ages 40+
AstraZeneca · Sites in China, United States, Argentina and 20 more countries
Ages 40+
Dragonboat Biopharmaceutical Company Limited · Sites in China
Ages 40+
Affiliated Hospital of Liaoning University of Traditional Chinese Medicine · Sites in China
Ages 40–85
Shanghai Pulmonary Hospital, Shanghai, China · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 84 Idiopathic Pulmonary Fibrosis studies recruiting now, 55 (65%) set no upper age limit and 7 (8%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 22 · Phase 2 24 · Phase 3 14
First in 2012; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 83 across the 60 interventional studies, 310 across the 7 observational. Of the 33 that completed or were terminated, 11 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 67 have an industry lead sponsor. The 10 most frequent:
Regend Therapeutics is the lead sponsor of 11 studies on the registry; 5 are open to participants now.
Regend Therapeutics has 3 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
7 of the studies in Idiopathic Pulmonary Fibrosis with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06125327Phase 3Guangzhou JOYO Pharma Co., LtdSC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | 2026-12-31 |
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT06267183Shanghai Synvida Biotechnology Co.,Ltd.A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. | 2026-11-30 |
| NCT07820254Shanghai Pulmonary Hospital, Shanghai, ChinaInspiratory Flow Rate Capability in Pulmonary Fibrosis Patients | 2026-12-31 |
| NCT07121413Shanghai Synvida Biotechnology Co.,Ltd.A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a prospective, single-arm, dose-escalation exploratory clinical trial to investigate the safety, tolerability and preliminary efficacy of REGEND007 stem cell preparation administered by intravenous infusion in the treatment of idiopathic pulmonary fibrosis (IPF), with a follow-up period of 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: REGEND007 Cell Therapy
This study's intravenous infusion dose escalation protocol is based on a 3+3 dose escalation design, with a total of 4 dose groups. Each group included 3 subjects, and the dose is gradually increased until the maximum tolerated dose(MTD) or the maximum administered dose (MAD) is reached.
The incidence and severity of drug-related adverse events (AEs)
All adverse medical events that occur from the time the subject signs the informed consent form. These can manifest as symptoms, signs, diseases, or abnormal laboratory test results, but they do not necessarily have a causal relationship with the investigational drug.
Time frame: 12 weeks after the administration
The change in the actual forced vital capacity (FVC) compared to the baseline
FVC is the full amount of air that can be-exhaled with effort in a complete breath
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration
The change in forced vital capacity (FVC) actual-to-predicted ratio compared to the baseline
The FVC actual-to-predicted ratio is a crucial indicator in pulmonary function tests, and it is mainly used to determine whether there is restrictive ventilation dysfunction.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.
The change in the actual forced expiratory volume in one second (FEV1) compared to the baseline
FEV1 is the volume of breath exhaled with effort in one second.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration
The change in the forced expiratory volume in one second (FEV1) actual-to-predicted ratio compared to the baseline
The FEV1 actual-to-predicted ratio is a crucial indicator in pulmonary function tests, representing the percentage relationship between the actual measured value of the first-second forced expiratory volume (FEV1) and the predicted value calculated based on individual characteristics. Under normal circumstances, the actual measured value of FEV1 should reach more than 80% of the predicted value.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration
The change in the carbon monoxide diffusion capacity (DLCO) compared to the baseline
DLCO is a measure of the conductance of CO across the alveolar-capillary membrane and its binding with hemoglobin.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration
The change in carbon monoxide diffusion capacity (DLCO) actual-to-predicted ratio compared to the baseline
DLCO actual-to-predicted ratio is a crucial indicator in pulmonary function testing, used to assess the oxygen exchange capacity and efficiency of the alveoli.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.
The change in the ratio of carbon monoxide diffusion capacity to lung alveolar volume (DLCO/VA) compared to the baseline
DLCO/VA is also known as the diffusion constant, since the diffusion amount is affected by the alveolar ventilation volume, a decrease in alveolar ventilation volume can lead to a reduction in DLCO. Therefore, this value is often used for correction to eliminate the influence of lung volume on the diffusion amount.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.
The change in the six-minute walk test (6MWT) compared to the baseline
6MWT is one of the commonly used methods in clinical practice for assessing a patient's cardiac and pulmonary functions, which involves measuring the distance that a patient can walk quickly on a flat and hard surface within 6 minutes.
Time frame: 24 hours after administration, 4 and 12 weeks after the last administration.
The time when the first acute exacerbation of IPF occurred after administration
The time when the first acute exacerbation of IPF occurred after administration is helpful for assessing disease progression and prognosis.
Time frame: Within 12 weeks after administration
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2026; primary completion for Feb 2027, 12 months later.
Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 12 months is above that.
Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Idiopathic Pulmonary Fibrosis →
Regend Therapeutics